ReviewJournal of diabetes research2014
Role of microRNAs in islet beta-cell compensation and failure during diabetes.
Review in Journal of diabetes research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus.International journal of molecular sciences · 2017Pooled it
- A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study.Experimental & molecular medicine · 2018Trial
- Beta cell microRNAs function as molecular hubs of type 1 diabetes pathogenesis and as biomarkers of diabetes risk.Diabetologia · 2026Article
- Multifaceted functions of transcription regulatory factor X6 (RFX6): from pancreatic development to cancer progression.Cancer cell international · 2025Review
- Comprehensive sequencing profile and functional analysis of IsomiRs in human pancreatic islets and beta cells.Diabetologia · 2025Article
- Clinical association and diagnostic significance of miRNA-29a and miRNA-147b in type 2 diabetes mellitus.International journal of medical sciences · 2023Article
- Milk Exosomal microRNAs: Postnatal Promoters of β Cell Proliferation but Potential Inducers of β Cell De-Differentiation in Adult Life.International journal of molecular sciences · 2022Review
- MiR-7-5p inhibits thyroid cell proliferation by targeting the EGFR/MAPK and IRS2/PI3K signaling pathways.Oncotarget · 2021Article
- Oxidized LDLs as Signaling Molecules.Antioxidants (Basel, Switzerland) · 2021Review
- The Landscape of microRNAs in βCell: Between Phenotype Maintenance and Protection.International journal of molecular sciences · 2021Review
- miR-344-5p Modulates Cholesterol-Induced β-Cell Apoptosis and Dysfunction Through Regulating Caveolin-1 Expression.Frontiers in endocrinology · 2021Article
- Early-Onset Diabetes as Risk Factor for Pancreatic Cancer: miRNA Expression Profiling in Plasma Uncovers a Role for miR-20b-5p, miR-29a, and miR-18a-5p in Diabetes of Recent Diagnosis.Frontiers in oncology · 2020Article
- MiR-132 controls pancreatic beta cell proliferation and survival through Pten/Akt/Foxo3 signaling.Molecular metabolism · 2020Article
- MicroRNA-223 is essential for maintaining functional β-cell mass during diabetes through inhibiting both FOXO1 and SOX6 pathways.The Journal of biological chemistry · 2019Article
- MicroRNA-18 promotes apoptosis of islet β-cells via targeting NAV1.Experimental and therapeutic medicine · 2019Article
- miR-132-3p is a positive regulator of alpha-cell mass and is downregulated in obese hyperglycemic mice.Molecular metabolism · 2019Article
- Beta cell secretion of miR-375 to HDL is inversely associated with insulin secretion.Scientific reports · 2019Article
- Role of TGF-β/Smad Pathway in the Transcription of Pancreas-Specific Genes During Beta Cell Differentiation.Frontiers in cell and developmental biology · 2019Article
- Maternal β-Cell Adaptations in Pregnancy and Placental Signalling: Implications for Gestational Diabetes.International journal of molecular sciences · 2018Review
- MicroRNA profiling and their pathways in South African individuals with prediabetes and newly diagnosed type 2 diabetes mellitus.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic beta-cell function and mass are markedly adaptive to compensate for the changes in insulin requirement observed during several situations such as pregnancy, obesity, glucocorticoids excess, or administration. This requires a beta-cell compensation which is achieved through a gain of beta-cell mass and function. Elucidating the physiological mechanisms that promote functional beta-cell mass expansion and that protect cells against death, is a key therapeutic target for diabetes. In this respect, several recent studies have emphasized the instrumental role of microRNAs in the control of beta-cell function. MicroRNAs are negative regulators of gene expression, and are pivotal for the control of beta-cell proliferation, function, and survival. On the one hand, changes in specific microRNA levels have been associated with beta-cell compensation and are triggered by hormones or bioactive peptides that promote beta-cell survival and function. Conversely, modifications in the expression of other specific microRNAs contribute to beta-cell dysfunction and death elicited by diabetogenic factors including, cytokines, chronic hyperlipidemia, hyperglycemia, and oxidized LDL. This review underlines the importance of targeting the microRNA network for future innovative therapies aiming at preventing the beta-cell decline in diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.